NEW YORK (GenomeWeb News) – Oncodesign today announced an agreement with Eisai to assess the use of Halaven Injection (eribulin) in earlier line treatment of metastatic breast cancer. 

Oncodesign will conduct in vivo pharmacology studies and Eisai will perform gene expression profiling analysis using Oncodesign's patient-derived xenograft models to evaluate Eisai's Halaven, a non-taxane microtubule dynamics inhibitor. Oncodesign could receive up to €1.25 million ($1.56 million) in revenue for its contributions and has received €900,000 to date, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.